Abstract: Orally administered low-dose formulations for medium chain di-carboxylic acids have unexpectedly a numerous of beneficial cytoprotective effects in a variety of cells. In particular, contemplated formulations compositions and methods reduce, reverse, and/or prevent liver inflammation, hepatic steatosis, and/or liver fibrosis in NASH, improve blood glucose control, and provide additional cytoprotective benefits such as stimulation of mitochondrial biogenesis, increased SIRT and NAMPT levels, increased NAD+, antioxidant capacity, and/or reduction of DNA damage.